An observational study in Aneuploidy, PGT-A and Chromosomal Abnormalities, sponsored by Fakih IVF Fertility Center. Recruiting at 1 site in United Arab Emirates. Open to participants aged 21 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Fakih IVF Fertility Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
For Couples undergoing in vitro fertilization (IVF), one of the most important decisions is choosing which embryo has the best chance of leading to a healthy pregnancy. Today, this often relies on a biopsy, where a few cells are removed from the embryo for genetic testing (PGT-A). This technique has shown high accuracy; however, this test is invasive, adds cost, and involves handling the embryo directly.
The Prediction of Embryo Aneuploidy using Non-invasive Morphokinetics and Culture Media Readouts (PEARL) Trial is testing a non-invasive alternative that combines two approaches. The first; time-lapse imaging using a camera-equipped incubator to continuously record how an embryo divides and grows, without ever removing it from its stable environment. The second; spent culture media testing by analyzing the fluid that the embryo grows in for biological signals (DNA fragments, microRNA, proteins, and metabolic byproducts) which the embryo releases as it develops.
By studying these two sources of information together, alongside each embryo's actual genetic result from standard PGT-A testing, we aim to find out whether imaging and fluid analysis, combined, can reliably predict whether an embryo is chromosomally normal (euploid) or abnormal (aneuploid) without needing a biopsy.
Taking part does not change a couple's standard IVF treatment. Embryos are cultured and tested exactly as they normally would be; the only difference is that imaging data and a small sample of fluid that would otherwise be thrown away are collected for research analysis. All embryo selection and transfer decisions continue to be based on the clinic's usual standard of care.
If successful, this approach could make embryo assessment safer, faster, and more affordable reducing the need for invasive testing in IVF, in Abu Dhabi and internationally.
Time-lapse imaging (TLI) enables continuous, non-invasive assessment of embryo development. Early cleavage timings (t2, t3), cell cycle durations (cc2, cc3), and synchrony measures (s2, s3) have been associated with developmental competence, while later morphokinetic events; compaction and blastocyst expansion, appear particularly informative for blastocyst quality and may carry signals related to chromosomal status.
In parallel, spent embryo culture media (SECM) studies report that cell-free DNA (cfDNA) fragments, microRNA expression patterns, metabolic profiles, and specific secreted proteins differ between embryos with divergent developmental and genetic outcomes, suggesting SECM as a complementary, non-invasive biomarker source.
However, methodological variability across studies; including inconsistent sample collection timing, inadequate contamination control, and heterogeneous assay platforms, limits reproducibility and has constrained clinical translation. Critically, no adequately powered, prospective study has yet integrated detailed morphokinetic profiling with multi-omic SECM assessment and validated the combined approach against preimplantation genetic testing for aneuploidy (PGT-A) as a reference standard.
The PEARL Trial addresses this gap through a large, prospective, standardized dataset combining TLI-derived morphokinetic parameters with multi-omic SECM analysis (cfDNA, microRNA, metabolomic, and proteomic markers), collected under controlled conditions to minimize pre-analytical variability. All embryos will undergo routine PGT-A per standard clinical protocol, providing ground-truth ploidy status against which combined predictive models will be evaluated.
The primary objective is to determine the correlation between integrated morphokinetic/SECM signatures and embryo ploidy, and to assess the predictive performance of a combined non-invasive model relative to PGT-A. Embryo culture and clinical decision-making will follow standard institutional protocols throughout, with TLI and SECM sampling embedded within existing laboratory workflows to avoid any deviation from standard-of-care embryo handling.
75 studies on the registry are indexed under Aneuploidy; 12 are open to participants now.
This study's planned enrollment of 200 is below the median of 290 across 40 observational studies indexed under Aneuploidy.
Browse Aneuploidy studies →Fakih IVF Fertility Center is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be selected from IVF patients attending the FAKIH IVF clinic in Abu Dhabi.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Embryo culture spent media collected and frozen, then for embryos which are identified as aneuploid by PGT-A, their frozen spent media and morphokinetics will be analyzed.
Other: No Intervention: Observational Cohort
This is an observation cohort. There are no interventions in this study.
miRNA expression profiles
miRNA expression profiles of spent media from embryo culture.
Time frame: Day 6 or 7 of embryo culture.
Correlation between spent media analysis and morphokinetics
Correlation between spent media analysis and morphokinetics in PGT-A confirmed Aneuploid embryos. Spent media harvested within 24 hours of embryo removal from culture media.
Time frame: Day 6 or 7 of embryo culture.
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fakih IVF Fertility Center